Velmetia Contraindications

metformin + sitagliptin


Merck Sharp & Dohme


Full Prescribing Info
SITAGLIPTIN PHOSPHATE + METFORMIN HCl (VELMETIA) is contraindicated in patients with: Severe renal impairment, (eGFR <30 mL/min/1.73 m2) (see Metformin hydrochloride: Renal Impairment under Precautions).
Known hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of SITAGLIPTIN PHOSPHATE + METFORMIN HCl (VELMETIA) (see Sitagliptin phosphate: Hypersensitivity Reactions under Precautions and Postmarketing Experience under Adverse Reactions).
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
SITAGLIPTIN PHOSPHATE + METFORMIN HCl (VELMETIA) should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see Metformin hydrochloride under Precautions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in